<DOC>
	<DOCNO>NCT00963768</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( ie , blood level JNJ-28431754 ) pharmacodynamics ( ie , urine blood level glucose ) JNJ-28431754 compare placebo patient Type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Study JNJ-28431754 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither physician , patient sponsor know assign treatment ) , placebo-controlled , single multiple ( 14 day ) ascend dose , parallel group study 3 study center ( United States , Germany South Korea ) . Five cohort ( group ) patient Type 2 diabetes mellitus ( T2DM ) study . One dose level evaluate cohort . Sixteen ( 16 ) patient randomly assign receive JNJ-28431754 four ( 4 ) patient receive match placebo within cohort . The planned dos 30 , 100 , 300 600 mg per day . Twice-daily dosing may also evaluate one cohort . An additional cohort Asian patient also evaluate dose level , previously test prior cohort consider well tolerate . Blood urine sample collect patient study pharmacokinetic pharmacodynamic assessment . The safety tolerability JNJ-28431754 monitor throughout study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Patients must diagnose Type 2 Diabetes least one year screening Patients must take stable dose oral ( mouth ) antidiabetic monotherapy combination two antidiabetic medication Males postmenopausal surgically sterile woman ( postmenopausal define menses least 18 month prior study start menses 6 18 month ) Body mass index ( weight kg/height m2 ) 20 39.9 kg/m2 History Type 1 , brittle diabetes secondary form diabetes History repeat severe hypoglycemic episode History diabetic complication include retinopathy , nephropathy , neuropathy , gastroparesis , ketoacidosis History , currently active illness include limited cardiovascular disease , hematological disease , respiratory disease , hepatic gastrointestinal disease , endocrine/metabolic disorder , neurologic psychiatric disease , malignant neoplasm consider Investigator clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Sodium Glucose Co-transporter ( SGLT2 inhibitor )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>